The Weekly Recap 12/19/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, announce an acquisition agreement, and much more on the road to LSI USA ’26 in Dana Point (March 16–20).

Adagio Medical

Appointed longtime Medtronic executive Sean Salmon to its Board of Directors, where he will also serve on the audit and compensation committees. Salmon’s deep operational experience and electrophysiology expertise will support Adagio as the company advances its ultra-low cryoablation technology for ventricular tachycardia.

CathVision

Appointed former Boston Scientific EMEA President Eric Thepaut as independent Chairman of the Board and released Version 3.5 of its ECGeniusⓇ System. The update adds hardware and software enhancements designed to improve workflow efficiency and system performance as the company prepares for commercial growth in the U.S. and Europe.

CMR Surgical

Announced that it has received FDA 510(k) clearance for Versius Plus, its second-generation surgical robot, for use in cholecystectomy procedures. With this clearance secured, the company plans to begin commercialization of Versius Plus in 2026.

CroíValve

Reported the world’s first transcatheter treatment of tricuspid regurgitation using its Duo Adapt system. The procedure was performed at Poznan University Hospital in Poland as part of the TANDEM II clinical study of Duo, which works in tandem with the native tricuspid valve to restore valve function.

Dilon Technologies

Received FDA approval for its MarginProbeⓇ 2 system and announced its launch in the U.S. MarginProbe 2 is the company’s next-generation intraoperative margin assessment device for breast-conserving surgery, designed to help surgeons improve precision to improve patient outcomes and reduce the need for additional procedures.

May Health

Announced that its Anavi™ System for PCOS-related infertility has received CE Mark certification. The Anavi System is a novel, one-time, office-based procedure designed to restore natural ovulation in women with PCOS-related infertility who don’t respond to, are contraindicated for, or have declined first-line medications.

Medical 21

Received regulatory approval in Spain to initiate its first-in-human MAVERICS Coronary Revascularization Study, evaluating the company’s regenerative small-diameter coronary bypass graft. The milestone advances clinical assessment of the MAVERICS graft, a synthetic vascular scaffold designed to provide a durable alternative to harvested vessels.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-121925-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more